A Phase 3, Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter Clinical Study of Eslicarbazepine Acetate in Post-Herpetic Neuralgia.
Phase of Trial: Phase III
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Eslicarbazepine acetate (Primary)
- Indications Postherpetic neuralgia
- Focus Registrational; Therapeutic Use
- Sponsors Bial
- 04 Apr 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 29 Nov 2013 Planned end date changed from 1 Sep 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
- 22 Jul 2013 Planned end date changed from 1 Apr 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.